Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02473484

Acronym

GLIOMIC

Enrollment

Registered

2015-06-16

Start date

2014-06-24

Completion date

2017-10-31

Last updated

2017-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Keywords

High Grade Glioma, Proteomics, MALDI-MSI

Brief summary

The aim is to classify high grade glioma by matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI). In order to provide more specific informations for the diagnosis and the prognosis of high grade glioma.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Main inclusion criteria: * Patients with grade III or IV glioma newly diagnosed with histological evidence * Surgical indication * Tumor tissue available at biobank of Lille * Men and women aged ≥ 18 years * Informed Consent signed by the patient or his legal representative. Main

Exclusion criteria

* Antecedents of other cancers except basal cell skin cancer or carcinoma in situ of the uterus cervix * Previous history of brain radiotherapy * Anti-tumor systemic treatments (chemotherapy or targeted therapy) prior to surgery of glioma * Genetic disease that may cause brain tumor, potentially radiation-induced tumor * History of degenerative neurological disease prior to diagnosis * contraindication to MRI

Design outcomes

Primary

Measure	Time frame
To evaluate the correlation between the WHO classification 2007 only established standard diagnostic and classification by mass spectrometry gliomas (lipids, peptides, proteins)	2.5 years

Countries

France

Outcome results